EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Acute Liver Failure following a Single Dose of Atezolizumab, as Assessed for Causality Using the Updated RUCAM

Roie Tzadok iD, Sharon Levy, Jessie Aouizerate, Oren Shibolet

Case Reports in Gastrointestinal Medicine · 23.03.2022 · 2022 · 1-4

DOI: 10.1155/2022/5090200 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Case Reports in Gastrointestinal Medicine, erschienen am 23.03.2022. Verfasst von Roie Tzadok und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine C, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors have become major therapeutic agents in oncology over the last few years. However, they are associated with a variety of potentially severe autoimmune phenomena. We present a patient with advanced adenocarcinoma of the lung, who presented with acute liver injury two weeks following his first treatment with atezolizumab, rapidly deteriorating to fulminant liver failure. A thorough evaluation of infectious, vascular, metabolic, and autoimmune etiologies did not yield any results. Liver pathology was nonspecific. Using RUCAM as a causality assessment method indicated probable connection between atezolizumab and liver damage. To our knowledge, this is the first documented report of a patient developing acute liver failure shortly after immune checkpoint inhibitor initiation.

Autor:innen und Institutionen

  • Department of Internal Medicine C, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Department of Gastroenterology and Hepatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Institute of Pathology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

ORCID-Profile: Roie Tzadok

Zitieren

APA

Tzadok, R., Levy, S., Aouizerate, J., & Shibolet, O. (2022). Acute Liver Failure following a Single Dose of Atezolizumab, as Assessed for Causality Using the Updated RUCAM. Case Reports in Gastrointestinal Medicine, 2022, 1-4. https://doi.org/10.1155/2022/5090200

Vancouver

Tzadok R, Levy S, Aouizerate J, Shibolet O. Acute Liver Failure following a Single Dose of Atezolizumab, as Assessed for Causality Using the Updated RUCAM. Case Reports in Gastrointestinal Medicine. 2022;2022:1-4. doi:10.1155/2022/5090200

BibTeX
@article{Tzadok2022,
  author = {Tzadok, Roie and Levy, Sharon and Aouizerate, Jessie and Shibolet, Oren},
  title = {Acute Liver Failure following a Single Dose of Atezolizumab, as Assessed for Causality Using the Updated RUCAM},
  journal = {Case Reports in Gastrointestinal Medicine},
  year = {2022},
  volume = {2022},
  pages = {1--4},
  doi = {10.1155/2022/5090200}
}
Kostenlos starten →